Antigen presentation and T cell stimulation by dendritic cells

Annual Review of Immunology

Volumn 20, Issue , 2002, Pages 621-667

  Guermonprez, Pierre ^a   Valladeau, Jenny ^a   Zitvogel, Laurence ^a   Théry, Clotilde ^a   Amigorena, Sebastian ^a  

^a INSTITUT CURIE   (France)

Author keywords

Class presentation; Endocytosis; Immunotherapy; MHC; T cell priming

Indexed keywords

CD1 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE RECEPTOR; FC RECEPTOR; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANZYME B; HEAT SHOCK PROTEIN; HLA A2 ANTIGEN; HLA ANTIGEN; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LECTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN; PROSTAGLANDIN E2; SCAVENGER RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INTERNALIZATION; KIDNEY CANCER; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MYELOMA; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PINOCYTOSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; VIRUS LOAD;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD1; CELL DIFFERENTIATION; CLINICAL TRIALS; CROSS REACTIONS; DENDRITIC CELLS; ENDOCYTOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHAGOCYTOSIS; PINOCYTOSIS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0036214292     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.20.100301.064828     Document Type: Review

References (312)

1. Dendritic cells and the control of immunity
2. Immunobiology of dendritic cells
3. Dendritic cells
4. The cell biology of antigen presentation in dendritic cells
5. Danger signals: SOS to the immune system
6. Dendritic cells: On the move from bench to bedside
7. The endocytic activity of dendritic cells
8. Accessory factors in clathrin-dependent synaptic vesicle endocytosis
9. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells
10. Membrane and soluble Fc gamma RII/III modulate the antigen-presenting capacity of murine dendritic epidermal Langerhans cells for IgG-complexed antigens
11. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes
12. Activation of human epidermal Langerhans cells by engagement of the high affinity receptor for IgE, Fc epsilon RI
13. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells
14. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing
15. Phagocytosis of antigens by Langerhans cells in vitro
16. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways
17. Cutting edge: Receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells
18. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
19. Recognizing death: The phagocytosis of apoptotic cells
20. Molecular cloning and functional characterization of a human scavenger receptor with C-type lectin (SRCL), a novel member of a scavenger receptor family
21. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
22. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing
23. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor
24. The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules
25. Binding and uptake of a galactosyl IgG by mannose receptor on macrophages and dendritic cells
26. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments
27. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells
28. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules
29. DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking
30. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria
31. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo
32. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection
33. Murine dendritic cells internalize Leishmania major promastigotes, produce IL-12 p40 and stimulate primary T cell proliferation in vitro
34. +) killer T cells
35. Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs
36. Dead or alive: Immunogenicity of human melanoma cells when presented by dendritic cells
37. Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response
38. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells
39. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells
40. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
41. Natural adjuvants: Endogenous activators of dendritic cells
42. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells
43. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells
44. Langerhans cells phagocytose vaginal epithelial cells undergoing apoptosis during the murine estrous cycle
45. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes
46. Corpse clearance defines the meaning of cell death
47. A receptor for phosphatidylserine-specific clearance of apoptotic cells
48. Phagocytosis and clearance of apoptotic cells is mediated by MER
49. Alphavbeta5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells
50. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
51. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium
52. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
53. Rac is required for constitutive macropinocytosis by dendritic cells but does not control its downregulation
54. Developmental control of endocytosis in dendritic cells by Cdc42
55. Mechanism of measles virus-induced suppression of inflammatory immune responses
56. Involvement of caveolae in the uptake of respiratory syncytial virus antigen by dendritic cells
57. Parasitism of epidermal Langerhans cells in experimental cutaneous leishmaniasis with Leishmania major
58. Histoplasma capsulatum yeasts are phagocytosed via very late antigen-5, killed, and processed for antigen presentation by human dendritic cells
59. Dendritic cells and the replication of HIV-1
60. Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus
61. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infection
62. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
63. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses
64. Innate immunity
65. Dendritic cells as sensors of infection
66. Toll-like receptors in the induction of the innate immune response
67. Regulation of Toll-like receptors in human monocytes and dendritic cells
68. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: Selective expression of TLR3 in dendritic cells
69. The role of toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of dendritic cell maturation and require TLR2
70. Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2
71. Mycoplasma fermentans lipoprotein M161 Ag-induced cell activation is mediated by Toll-like receptor 2: Role of N-terminal hydrophobic portion in its multiple functions
72. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway
73. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens
74. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal
75. +) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli
76. Activation of human dendritic cells through CD40 cross-linking
77. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: A new role for Fas ligand in inflammatory responses
78. Expression and function of OX40 ligand on human dendritic cells
79. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization
80. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses
81. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
82. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
83. Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming
84. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway
85. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor
86. Endocytosed heat shock protein 60s use TLR2 and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells
87. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex
88. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine
89. Cutting edge: Heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells
90. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells
91. Dendritic cell survival and maturation are regulated by different signaling pathways
92. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells
93. CD40 signaling in human dendritic cells is initiated within membrane rafts
94. Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells
95. GADD45 gamma mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector TH1 cells
96. + monocytes through distinct pathways that activate NK-kappa B
97. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice
98. The human toll signaling pathway: Divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6)
99. Endotoxin-induced maturation of myd88-deficient dendritic cells
100. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression
101. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking
102. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay
103. The nature of the MHC class I peptide loading complex
104. Bacteria-induced neo-biosynthesis, stabilization, and surface expression of functional class I molecules in mouse dendritic cells
105. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells
106. Maturation, activation, and protection of dendritic cells induced by double-stranded RNA
107. Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation
108. Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells
109. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
110. Identification and analysis of a novel member of the ubiquitin family expressed in dendritic cells and mature B cells
111. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells
112. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
113. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
114. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis
115. The efficiency of antigen delivery from macrophage phagosomes into cytoplasm for MHC class I-restricted antigen presentation
116. Processing of bacterial antigens for peptide presentation on MHC class I molecules
117. +) T cells by dendritic cells
118. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses
119. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
120. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
121. Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells
122. Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: Role of opsonizing anti-beta2-glycoprotein I antibodies
123. Exogenous antigen targeted to FcgammaRI on myeloid cells is presented in association with MHC class I
124. Influences of transporter associated with antigen processing (TAP) on the repertoire of peptides associated with the endoplasmic reticulum-resident stress protein gp96
125. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules
126. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis
127. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens
128. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M) beta(2) integrin (CD11b/CD18)
129. + T cell responses to infectious agents, tumors, transplants, and vaccines
130. Recycling MHC class I molecules and endosomal peptide loading
131. Antigen loading of MHC class I molecules in the endocytic tract
132. Colocalization of Fc gamma RI-targeted antigen with class I MHC: Implications for antigen processing
133. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
134. Impaired immune responses and altered peptide repertoire in tapasin-deficient mice
135. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages
136. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells
137. Intrathymic deletion of MHC class I-restricted cytotoxic T cell precursors by constitutive cross-presentation of exogenous antigen
138. + T cells results in antigen-specific T-cell tolerance
139. In vivo cross-priming of MHC class I-restricted antigens requires the TAP transporter
140. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
141. Invariant chain structure and MHC class II function
142. Proteases involved in MHC class II antigen presentation
143. The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules
144. Antigen processing in the endocytic compartment
145. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli
146. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells
147. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
148. Invariant chain controls H2-M proteolysis in mouse splenocytes and dendritic cells
149. Developmental regulation of MHC class II transport in mouse dendritic cells
150. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells
151. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice
152. Cathepsin S required for normal MHC class II peptide loading and germinal center development
153. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells
154. Dendritic cell maturation and antigen presentation in the absence of invariant chain
155. MHC class II expression is regulated in dendritic cells independently of invariant chain degradation
156. Extracellular antigen processing and presentation by immature dendritic cells
157. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms
158. Transport of peptide-MHC class II complexes in developing dendritic cells
159. Modulation of MHC class II transport and lysosome distribution by macrophage-colony stimulating factor in human dendritic cells derived from monocytes
160. The CD1 system: Antigen-presenting molecules for T cell recognition of lipids and glycolipids
161. Presentation of self and microbial lipids by CD1 molecules
162. CD1 and lipid antigens: Intracellular pathways for antigen presentation
163. Separate pathways for antigen presentation by CD1 molecules
164. CD1a molecules traffic through the early recycling endosomal pathway in human Langerhans cells
165. CD1c molecules broadly survey the endocytic system
166. Intersection of group I CD1 molecules and mycobacteria in different intracellular compartments of dendritic cells
167. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides
168. Human CD1b and CD1c isoforms survey different intracellular compartments for the presentation of microbial lipid antigens
169. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families
170. Murine CD1d-restricted T cell recognition of cellular lipids
171. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments
172. Antigen-presenting function of the mouse CD1 molecule
173. CD1d on myeloid dendritic cells stimulates cytokine secretion from and cytolytic activity of V alpha 24J alpha Q T cells: A feedback mechanism for immune regulation
174. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells
175. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes
176. Dendritic cell maturation overrules H-2D-mediated natural killer (NKT) cell inhibition: Critical role for B7 in CD1d-dependent NKT cell IFNγ production
177. Characterization of CD1e, a third type of CD1 molecule expressed in dendritic cells
178. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ
179. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
180. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells
181. Enumeration of antigen-presenting cells in mice infected with Sendai virus
182. Characterization of sheep afferent lymph dendritic cells and their role in antigen carriage
183. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells
184. Antigen-unspecific B cells and lymphoid dendritic cells both show extensive surface expression of processed antigen-major histocompatibility complex class II complexes after soluble protein exposure in vivo or in vitro
185. Analysis of adjuvant function by direct visualization of antigen presentation in vivo: Endotoxin promotes accumulation of antigen-bearing dendritic cells in the T cell areas of lymphoid tissue
186. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope
187. + T cells after gene gun immunization
188. +) T cells
189. Neonatal tolerance revisited: Turning on newborn T cells with dendritic cells
190. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt ligand as an adjuvant
191. Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity
192. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
193. Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue
194. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model
195. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
196. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo
197. Intrathymic presentation of circulating non-MHC antigens by medullary dendritic cells. An antigen-dependent microenvironment for T cell differentiation
198. Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins
199. The mode of protein antigen administration determines preferential presentation of peptide-class II complexes by lymph node dendritic or B cells
200. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes
201. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion
202. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo
203. Are dendritic cells the key to liver transplant tolerance?
204. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
205. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens
206. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation
207. + T-cell tolerance by cross-presentation of self antigens
208. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo
209. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
210. Cell-associated ovalbumin is cross-presented much more efficiently than soluble ovalbumin in vivo
211. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?
212. Parentage and heritage of dendritic cells
213. -) dendritic cells in vivo
214. +) dendritic cells
215. -) dendritic cells cross-prime cytotoxic T cells in vivo
216. -- subclasses of dendritic cells direct the development of distinct T helper cells in vivo
217. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo
218. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis
219. + dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node
220. Dendritic cell lineage, plasticity and cross-regulation
221. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand
222. Reciprocal control of T helper cell and dendritic cell differentiation
223. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
224. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
225. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
226. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
227. Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells
228. +) T cells mediate CD40-independent maturation of dendritic cells in vivo
229. + T cell help
230. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity
231. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
232. + T-helper and a T-killer cell
233. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
234. Dendritic cells require maturation via CD40 to generate protective antitumor immunity
235. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
236. +) cytotoxic T lymphocytes
237. CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: Critical role in migration from the tumor site to draining lymph nodes
238. The induction of tolerance by dendritic cells that have captured apoptotic cells
239. Differentiation of T regulatory cells by immature dendritic cells
240. Dendritic cells as a tool to induce anergic and regulatory T cells
241. +) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells
242. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
243. --) prolong cardiac allograft survival in nonimmuno-suppressed recipients
244. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
245. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
246. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon
247. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization
248. Natural interferon alpha/beta-producing cells link innate and adaptive immunity
249. Sensing pathogens and tuning immune responses
250. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells
251. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity
252. Human monocyte-derived dendritic cells induce naive T cell differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of stimulator/responder ratio
253. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells
254. The duration of antigenic stimulation determines the fate of naive and effector T cells
255. The CD8 response on autopilot
256. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo
257. Antigen-specific T lymphocytes regulate lipopolysaccharide-induced apoptosis of dendritic cells in vivo
258. + T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity
259. +) T cells in vivo: Implications for adaptive immunotherapy
260. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells
261. MHC class II and CD40 play opposing roles in dendritic cell survival
262. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
263. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
264. Tumor necrosis factor alpha maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation
265. Depressed Langerhans cell migration and reduced contact hypersensitivity response in mice lacking TNF receptor p75
266. Cutting edge: Resistance to apoptosis and continuous proliferation of dendritic cells deficient for TNF receptor-1
267. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway
268. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis
269. Differential susceptibility to CD95 (Apo-1/Fas) and MHC class II-induced apoptosis during murine dendritic cell development
270. The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites
271. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells
272. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer
273. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses
274. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias
275. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response
276. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
277. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
278. Viral vectors for dendritic cell-based immunotherapy
279. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization
280. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
281. Tumor-dendritic cell fusion technology and immunotherapy strategies
282. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
283. Induction of antitumor immunity using bone marrow-generated dendritic cells
284. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
285. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells
286. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro
287. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
288. +), interferon-gamma-secreting, T lymphocytes
289. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells
290. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells
291. + cytotoxic-T-cell responses: Evidence for immuno-selection of antigen-loss variants in vivo
292. Immune selection after antigen-specific immunotherapy of melanoma
293. Tumor-specific killer cells in paraneoplastic cerebellar degeneration
294. Compartmentalization of bacterial antigens: Differential effects on priming of CD8 T cells and protective immunity
295. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
296. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
297. Dendritic cell-based immunotherapy of cancer
298. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
299. Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatment
300. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
301. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
302. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
303. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
304. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
305. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen-pulsed dendritic cells
306. +) hematopoietic progenitor cells
307. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
308. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients
309. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes
310. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73
311. Proteomic analysis of dendritic cell-derived exosomes: A secreted subcellular compartment distinct from apoptotic vesicles